Clik here to view.
200 healthcare decision-makers gather to address the looming challenges of...
LONDON, 01-Dec-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address...
View ArticleSanofi discontinues clinical development of its experimental Clostridium...
PARIS, 05-Dec-2017 — /EuropaWire/ — Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III Cdiffense clinical trial program concluded that the...
View ArticleSanofi’s Toujeo® met primary objective in the first head-to-head clinical...
First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec PARIS, 05-Dec-2017 — /EuropaWire/ — Sanofi’s Toujeo®...
View ArticleClik here to view.
Sanofi acquires Bioverativ Inc., a biopharmaceutical company focused on...
Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases Adds leader in the growing hemophilia market and provides platform for expansion in other rare blood disorders...
View ArticleSanofi: the waiting period under the Hart-Scott-Rodino Antitrust Improvements...
PARIS, 26-Feb-2018 — /EuropaWire/ — Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s...
View ArticleJohn C. Reed, M.D. Ph.D. to succeed Elias Zerhouni, M.D. as Head of Global...
PARIS, 25-Apr-2018 — /EuropaWire/ — Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the...
View ArticleDupixent demonstrated significant improvement in multiple asthma endpoints in...
Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with uncontrolled asthma, irrespective of...
View ArticleSanofi launches worldwide stock purchase plan reserved for its employees
A plan taking place in almost 80 countries Subscription per five shares entitle the employee to one matching share[1] PARIS, 12-Jun-2018 — /EuropaWire/ — Sanofi launches today “Action 2018”, a...
View ArticleSanofi completes the divestment of its European generics business Zentiva to...
PARIS, 04-Oct-2018 — /EuropaWire/ — Sanofi has completed the previously announced divestment of its European generics business Zentiva to Advent International (Advent) effective September 30. The...
View ArticleClik here to view.
Sanofi announces second collaboration as it strives to develop a novel...
Sanofi announces second collaboration as it strives to develop a novel COVID-19 vaccine candidate (PRESS RELEASE) PARIS and LEXINGTON, MA, U.S.A, 27-Mar-2020 — /EuropaWire/ — Sanofi Pasteur...
View ArticleClik here to view.
COVID-19: Sanofi increases production capacity of hydroxychloroquine; commits...
COVID-19: Sanofi increases production capacity of hydroxychloroquine; commits to donate 100 million doses Sanofi to provide Plaquenil® (hydroxychloroquine) wherever possible, while securing appropriate...
View ArticleClik here to view.
Immune-mediated diseases biopharmaceutical Principia Biopharma Inc. acquired...
Immune-mediated diseases biopharmaceutical Principia Biopharma Inc. acquired by Sanofi for approximately EUR 3.1 billion ($3.68 billion) Further strengthens core R&D areas of autoimmune and...
View ArticleClik here to view.
Sanofi tender offer for Principia Biopharma outstanding shares, August 28 –...
Sanofi tender offer for Principia Biopharma outstanding shares, August 28 – September 25, 2020 (PRESS RELEASE) PARIS, 28-Aug-2020 — /EuropaWire/ — French multinational pharmaceutical company Sanofi...
View ArticleClik here to view.
Dr. Jean-Christophe Rufin to succeed Xavier Darcos as President of Sanofi...
Dr. Jean-Christophe Rufin to succeed Xavier Darcos as President of Sanofi Espoir Corporate Foundation (PRESS RELEASE) PARIS, 18-Sep-2020 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical...
View ArticleClik here to view.
ESMO Virtual Congress 2020: Libtayo positive pivotal data offer hope for the...
ESMO Virtual Congress 2020: Libtayo positive pivotal data offer hope for the treatment of advanced basal cell carcinoma, a difficult-to-treat cancer Libtayo is the first investigational medicine to...
View ArticleClik here to view.
The COVID-19 vaccine based on Sanofi’s recombinant protein-based technology...
The COVID-19 vaccine based on Sanofi’s recombinant protein-based technology and GSK’s pandemic adjuvant system secures 300 million doses order from the European Commission (EC) Agreement signed today...
View ArticleClik here to view.
Sanofi gains full global rights to a promising antibody for inflammatory...
Sanofi gains full global rights to a promising antibody for inflammatory disorders with the acquisition of Kymab Source: Kymab (PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French...
View ArticleClik here to view.
Sanofi launches more impactful Corporate Social Responsibility (CSR) strategy
Sanofi launches more impactful Corporate Social Responsibility (CSR) strategy Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity...
View ArticleClik here to view.
Drugs for Neglected Diseases initiative: first all-oral treatment for Human...
Sanofi announces second collaboration as it strives to develop a novel COVID-19 vaccine candidate (PRESS RELEASE) PARIS, 20-Jul-2021 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical...
View ArticleClik here to view.
Sanofi to add Rezurock™ to its transplant portfolio with the acquisition of...
Sanofi to add Rezurock to its transplant portfolio with the acquisition of Rezurock(belumosudil) to its transplant portfolio Adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for...
View Article
